The erectile dysfunction tx market sales are at an all-time

Domestic market share 89%

Last year, the erectile dysfunction treatment market size was 129.1 billion

Domestic product market share '83.8→88.9%' in 4 years

Hanmi Pharmaceutical PalPal Leads for 7 Consecutive Years.

 

Continuation of Dominant System Last year, the domestic erectile dysfunction treatment market grew to the largest ever.

 

Domestic companies' generic products dominated the market, accounting for nearly 90% of the market.

 

According to IQVIA, a drug research institute on the 8th, the size of the erectile dysfunction treatment market last year was 129.1 billion won, up 9.1% from the previous year.

 

Following 2021, it broke the record for the second consecutive year.

 

After recording 113.9 billion won in 2019, the erectile dysfunction treatment market recorded a downward trend to 112.4 billion won the following year.

 

At the time, it was evaluated that growth was dampened as patients' visits to hospitals and clinics decreased due to the prolonged Corona 19 and restrictions were placed on sales marketing activities.

 

It succeeded in rebounding by 5.2% from the previous year to 118.3 billion won in 2021 and continued to grow last year.

 

Products released by domestic pharmaceutical companies dominated the erectile dysfunction treatment market.

 

Last year, sales of erectile dysfunction treatments by domestic companies totaled 114.7 billion won, up 10.8% from the previous year.

 

It increased by 26.6% over four years from 90.6 billion won in 2018, showing a steady rise.

 

Last year, domestic companies accounted for 88.9% of the erectile dysfunction treatment market.

 

It continued to rise every year from 83.8% in 2018.

 

The multinational pharmaceutical company's erectile dysfunction treatment products are Viagra and Cialis.

 

Generic products released by domestic pharmaceutical companies overwhelm original products.

 

Looking at the sales of major products, Hanmi Pharmaceutical's PalPal still showed off its unrivaled prestige in the market.

 

PalPal is a generic product of Viagra.

 

Last year, PalPal's sales increased by 6.3% year-on-year to 21.8 billion won.

 

PalPal's market share in the entire erectile dysfunction treatment market reached 16.9%, so it was influential in the market.

 

PalPal overtook Viagra in the second quarter of 2013, one year after its release, and surpassed Cialis in the fourth quarter of 2015, becoming the leader in erectile dysfunction treatment sales.

 

PalPal has never fallen from the leading position for seven years from the fourth quarter of 2015 to last year.

 

PalPal more than doubled the sales of the original product Viagra (8.7 billion won).

 

Considering that the price of PalPal is significantly lower than that of Viagra, it is possible to calculate that the prescription volume gap is much larger.

 

Chong Kun Dang's Cendom ranked second with sales of 11.4 billion won last year, up 6.1% from the previous year.

 

Hanmi Pharm's Gugu recorded sales of 11.4 billion won, up 18.5% from the previous year, exceeding 10 billion won in annual sales for the first time.

 

Cendom and Gugu are generics of Cialis.

 

Among all erectile dysfunction drugs, only three products (PalPal, Cendom, and Gugu) exceeded 10 billion won in sales.

 

Released after Cialis' patent expired in September 2015, Cendom gradually expanded its market share, surpassing the original product Cialis in the fourth quarter of 2017.

 

In the fourth quarter of 2018, it maintained its second place since surpassing Viagra.

 

Gugu surpassed Cialis in the second quarter of 2019 and also surpassed Viagra in the second quarter of 2021.

 

Sales of Viagra and Cialis, which had built the two major mountain ranges of erectile dysfunction treatments in the past, have gradually decreased.

 

Viagra's sales last year were 8.7 billion won, down 1.1 percent from the previous year.

 

It decreased by 12.3% in 4 years from 9.9 billion won in 2018.

 

Last year, sales of Cialis recorded 5.7 billion won, down 5.2% from the previous year.

 

It fell 22.8% over four years from 7.4 billion won in 2018.